Population
Patients with cancer and established venous thromboembolism (VTE)
Design
Guideline
Authors
Loading...
LMWH becomes standard for cancer-associated VTE; confirms Level 1 consensus and directs future DOAC evaluation.
This Canadian consensus guideline establishes low molecular weight heparin as the standard of care for treating established venous thromboembolism in cancer patients.
Easaw et al. (2015) conducted a review in Venous thromboembolism in patients with cancer. Low molecular weight heparin was evaluated. Low molecular weight heparin is the treatment of choice for cancer patients with established venous thromboembolism, whereas direct oral anticoagulants are not recommended at this time.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: